+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kidney Fibrosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook

  • ID: 5130099
  • Report
  • July 2020
  • Region: Global
  • 132 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AdAlta Ltd
  • Cellmid Ltd
  • Fibrocor Therapeutics LP
  • iBio Inc
  • Max Biopharma Inc
  • Oasis Pharmaceuticals LLC
  • MORE
2020 Kidney Fibrosis PIPELINE HIGHLIGHTS

Kidney Fibrosis is one of the widely researched conditions during 2020 with 32 companies actively focusing on realizing pipeline’s potential. Development of Kidney Fibrosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Kidney Fibrosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Kidney Fibrosis.

Good progress is anticipated during 2020 and 2021 with Kidney Fibrosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Kidney Fibrosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Kidney Fibrosis DRUG DEVELOPMENT PIPELINE OVERVIEW

The “Kidney Fibrosis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Kidney Fibrosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Kidney Fibrosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Kidney Fibrosis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Kidney Fibrosis DRUG PROFILES

Kidney Fibrosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Kidney Fibrosis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Kidney Fibrosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Kidney Fibrosis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 32 Kidney Fibrosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Kidney Fibrosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- AdAlta Ltd, Algernon Pharmaceuticals Inc, Angion Biomedica Corp, BiOrion Technologies BV, Blade Therapeutics Inc, Cellmid Ltd, Curacle Co Ltd, Epigen Biosciences Inc, Evotec AG, Fibrocor Therapeutics LP, Future Medicine Co Ltd, Galectin Therapeutics Inc, GenKyoTex SA, iBio Inc, Isarna Therapeutics GmbH, Kadmon Corp LLC, Liminal BioSciences Inc, Max Biopharma Inc, MedPacto Inc, Mission Therapeutics Ltd, NB Health Laboratory Co Ltd, Novo Nordisk AS, Oasis Pharmaceuticals LLC, Osteoneurogen Inc, Pharmaxis Ltd, Redx Pharma Plc, Sanofi, Scholar Rock Inc, TiumBio Co Ltd, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Vectus Biosystems Ltd

Reasons to Buy
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Kidney Fibrosis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AdAlta Ltd
  • Cellmid Ltd
  • Fibrocor Therapeutics LP
  • iBio Inc
  • Max Biopharma Inc
  • Oasis Pharmaceuticals LLC
  • MORE
1. Introduction to Kidney Fibrosis
1.1 Kidney Fibrosis- Disease overview
1.2 Kidney Fibrosis- Market Size
1.3 Kidney Fibrosis- Companies Involved

2. Kidney Fibrosis Pipeline Snapshot- 2020
2.1 Kidney Fibrosis Pipeline by Phase
2.2 Kidney Fibrosis Pipeline by Mechanism of Action
2.3 Kidney Fibrosis Pipeline by Route of Administration
2.4 Kidney Fibrosis Pipeline- New Molecular Entities
2.5 Kidney Fibrosis Pipeline- Orphan Drug Designation/ Special Designation

3. Kidney Fibrosis Drug Profiles
3.1 Current Status
3.2 Kidney Fibrosis Drug Snapshot
3.3 Kidney Fibrosis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME

4. Company wise Pipeline and Trials
4.1 AdAlta Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.2 Algernon Pharmaceuticals Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.3 Angion Biomedica Corp Kidney Fibrosis Pipeline Insights and Clinical Trials
4.4 BiOrion Technologies BV Kidney Fibrosis Pipeline Insights and Clinical Trials
4.5 Blade Therapeutics Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.6 Cellmid Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.7 Curacle Co Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.8 Epigen Biosciences Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.9 Evotec AG Kidney Fibrosis Pipeline Insights and Clinical Trials
4.10 Fibrocor Therapeutics LP Kidney Fibrosis Pipeline Insights and Clinical Trials
4.11 Future Medicine Co Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.12 Galectin Therapeutics Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.13 GenKyoTex SA Kidney Fibrosis Pipeline Insights and Clinical Trials
4.14 iBio Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.15 Isarna Therapeutics GmbH Kidney Fibrosis Pipeline Insights and Clinical Trials
4.16 Kadmon Corp LLC Kidney Fibrosis Pipeline Insights and Clinical Trials
4.17 Liminal BioSciences Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.18 Max Biopharma Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.19 MedPacto Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.20 Mission Therapeutics Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.21 NB Health Laboratory Co Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.22 Novo Nordisk AS Kidney Fibrosis Pipeline Insights and Clinical Trials
4.23 Oasis Pharmaceuticals LLC Kidney Fibrosis Pipeline Insights and Clinical Trials
4.24 Osteoneurogen Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.25 Pharmaxis Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.26 Redx Pharma Plc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.27 Sanofi Kidney Fibrosis Pipeline Insights and Clinical Trials
4.28 Scholar Rock Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.29 TiumBio Co Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.30 TRACON Pharmaceuticals Inc Kidney Fibrosis Pipeline Insights and Clinical Trials
4.31 Vascular Biogenics Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials
4.32 Vectus Biosystems Ltd Kidney Fibrosis Pipeline Insights and Clinical Trials

5. Kidney Fibrosis Market News and Updates

6. Appendix
6.1 Sources and Methodology
6.2 Contact Information
Note: Product cover images may vary from those shown
3 of 3
  • AdAlta Ltd
  • Algernon Pharmaceuticals Inc
  • Angion Biomedica Corp
  • BiOrion Technologies BV
  • Blade Therapeutics Inc
  • Cellmid Ltd
  • Curacle Co Ltd
  • Epigen Biosciences Inc
  • Evotec AG
  • Fibrocor Therapeutics LP
  • Future Medicine Co Ltd
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • iBio Inc
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Liminal BioSciences Inc
  • Max Biopharma Inc
  • MedPacto Inc
  • Mission Therapeutics Ltd
  • NB Health Laboratory Co Ltd
  • Novo Nordisk AS
  • Oasis Pharmaceuticals LLC
  • Osteoneurogen Inc
  • Pharmaxis Ltd
  • Redx Pharma Plc
  • Sanofi
  • Scholar Rock Inc
  • TiumBio Co Ltd
  • TRACON Pharmaceuticals Inc
  • Vascular Biogenics Ltd
  • Vectus Biosystems Ltd
Note: Product cover images may vary from those shown
Adroll
adroll